[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 4 of about 4
1. Paulino AC, Wen BC, Brown CK, Tannous R, Mayr NA, Zhen WK, Weidner GJ, Hussey DH: Late effects in children treated with radiation therapy for Wilms' tumor. Int J Radiat Oncol Biol Phys; 2000 Mar 15;46(5):1239-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late effects in children treated with radiation therapy for Wilms' tumor.
  • PURPOSE: To determine the frequency and types of late effects in children receiving radiation therapy (RT) for Wilms' tumor.
  • MATERIALS AND METHODS: From 1968 to 1994, 55 children received megavoltage RT at our institution as part of treatment for Wilms' tumor.
  • There were 25 female and 17 male patients with a median age at diagnosis of 48 months (range, 7-126 months).
  • There were 12 Stage I, eight Stage II, 15 Stage III, six Stage IV, and one Stage V patient.
  • Whole-lung RT was delivered to 13 patients either at diagnosis or pulmonary relapse.
  • All patients received chemotherapy; the most common agents were actinomycin-D/vincristine/adriamycin in 13 and actinomycin-D/vincristine in 18.
  • The 10- and 15-year actuarial incidences of scoliosis for Group A and B patients were 37.7 +/- 12.4% and 37.7 +/- 12.4%, whereas for Group C patients the incidences were 65.8 +/- 12.0% and 74.4 +/- 11.
  • The actuarial incidence of bowel obstruction at 5, 10, and 15 years was 9.5 +/- 4.5%, 13.0 +/- 5.6%, and 17.0 +/- 6.5%.
  • Of 23 patients, five irradiated within 10 days of surgery and one of 19 irradiated after 10 days developed bowel obstruction (p = 0.09, log rank test).
  • Four patients developed benign neoplasms; three were in the RT field (two osteochondroma, one lipoma) and one outside (cervical intraepithelial neoplasia II).
  • There were three second malignancies (chronic myelogenous leukemia at 9 years, osteosarcoma at 11 years, and breast cancer at 25 years after initial diagnosis of nephroblastoma); both solid malignancies occurred in the RT field.
  • CONCLUSIONS: Late effects of therapy were seen in more than two thirds of children treated for Wilms' tumor.
  • [MeSH-major] Kidney Neoplasms / radiotherapy. Radiation Injuries / complications. Wilms Tumor / radiotherapy
  • [MeSH-minor] Child. Child, Preschool. Dose-Response Relationship, Radiation. Female. Fertility / radiation effects. Follow-Up Studies. Humans. Infant. Intestinal Obstruction / etiology. Intestine, Small / radiation effects. Kidney Diseases / etiology. Kyphosis / etiology. Male. Muscles / radiation effects. Neoplasm Staging. Neoplasms, Second Primary / etiology. Puberty, Delayed / etiology. Scoliosis / etiology. Time Factors


2. Knudsen AL, Bülow S: [Desmoid tumor in familial adenomatous polyposis]. Ugeskr Laeger; 2000 Oct 16;162(42):5628-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Desmoid tumor in familial adenomatous polyposis].
  • [Transliterated title] Desmoid tumor ved familiaer adenomatøs polypose.
  • INTRODUCTION: Desmoid tumors (DT) are rare benign tumors that do not metastasize, but tend to invade locally.
  • DT are frequently seen in patients with familial adenomatous polyposis (FAP), and diagnosis and treatment are often difficult.
  • METHOD: The article presents the clinical picture, diagnosis and treatment of DT in patients registered in the Danish Polyposis Register by the end of 1999.
  • Fifty percent of the patients had complications (intestinal obstruction, hydronephrosis or fistulas), and 2/9 deaths were caused by DT.
  • Ninety-three percent were treated with surgery, NSAIDs, antioestogenic drugs, chemotherapy or radiotherapy, but all modalities proved disappointing, except for treatment with a combination of the NSAID sulindac and tamoxifen.
  • Elective surgery may be considered in patients with a small well-defined DT with no signs of invasion of vital structures, and in patients with imminent bowel ischaemia or obstruction.
  • [MeSH-minor] Adult. Antineoplastic Agents / administration & dosage. Colectomy. Colonic Neoplasms / complications. Colonic Neoplasms / diagnosis. Colonic Neoplasms / surgery. Combined Modality Therapy. Female. Humans. Male. Prognosis. Registries


3. Ferraretto A, Gravaghi C, Donetti E, Cosentino S, Donida BM, Bedoni M, Lombardi G, Fiorilli A, Tettamanti G: New methodological approach to induce a differentiation phenotype in Caco-2 cells prior to post-confluence stage. Anticancer Res; 2007 Nov-Dec;27(6B):3919-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Various differentiation-inducing agents or harvesting of spontaneously late post-confluence cultures have been used to differentiate the human colon carcinoma Caco-2 cell line.
  • RESULTS: Subcultures of Caco-2 cells at pre-confluence, exhibiting progressive acquisition of a more benign differentiation phenotype, were generated.
  • Early passages of Caco-2 cells showed a well-developed brush border and incomplete junctional apparatus; subsequent subcultures yielded cell populations with well-developed junctions similar to those of small intestinal cells.
  • CONCLUSION: These culture conditions represent a new versatile model not only to progressively induce the differentiation program in Caco-2 cells at pre-confluence without changes of culture media, but also to explore mechanistic modes of drug transport and tumor development.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18225551.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


Advertisement
4. Reid BJ: Early events during neoplastic progression in Barrett's esophagus. Cancer Biomark; 2010;9(1-6):307-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Barrett's esophagus is a condition in which the stratified squamous epithelium of the distal esophagus is replaced by specialized intestinal metaplasia.
  • Clinical management of Barrett's esophagus, like many other "premalignant" conditions, is characterized by overdiagnosis of benign early changes that will not cause death or suffering during the lifetime of an individual and underdiagnosis of life-threatening early disease.
  • Recent studies of a number of different types of cancer have revealed much greater genomic complexity than was previously suspected.
  • Specialized intestinal metaplasia has many properties that appear to be protective adaptations to the abnormal environment of gastroesophageal reflux.
  • Small, spatial scale studies have been used to infer the temporal order in which genomic abnormalities develop during neoplastic progression in Barrett's esophagus.
  • These spatial studies have provided the basis for prospective cohort studies of biomarkers, including DNA content abnormalities (tetraploidy, aneuploidy) and a biomarker panel of 9p LOH, 17p LOH and DNA content abnormalities.

  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastroenterol. 2006 Dec;41(12):1186-96 [17287898.001]
  • [Cites] PLoS Med. 2007 Feb;4(2):e67 [17326708.001]
  • [Cites] Am J Gastroenterol. 2007 Mar;102(3):483-93; quiz 694 [17338734.001]
  • [Cites] Int J Cancer. 2007 May 1;120(9):1914-21 [17236199.001]
  • [Cites] Genes Chromosomes Cancer. 2007 Jun;46(6):532-42 [17330261.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 Jul;293(1):G264-70 [17431220.001]
  • [Cites] J Mol Med (Berl). 2007 Jul;85(7):733-43 [17415542.001]
  • [Cites] Gastrointest Endosc. 2007 Sep;66(3):460-8 [17643436.001]
  • [Cites] N Engl J Med. 1992 Mar 12;326(11):737-40 [1445507.001]
  • [Cites] Gastroenterol Clin North Am. 1991 Dec;20(4):791-816 [1787014.001]
  • [Cites] Hum Pathol. 1992 May;23(5):479-82 [1568744.001]
  • [Cites] Cancer Res. 1992 May 15;52(10):2946-50 [1581911.001]
  • [Cites] Gastroenterol Clin Biol. 1991;15(10):703-10 [1816011.001]
  • [Cites] Gut. 1992 May;33(5):587-91 [1351861.001]
  • [Cites] Gut. 1992 Jun;33(6):733-7 [1624150.001]
  • [Cites] Gastroenterology. 1992 Dec;103(6):1769-76 [1360434.001]
  • [Cites] Cancer Res. 1993 Mar 15;53(6):1322-7 [8443812.001]
  • [Cites] Endoscopy. 1993 Nov;25(9):648-51 [8119224.001]
  • [Cites] Cancer Res. 1994 May 1;54(9):2292-5 [8162566.001]
  • [Cites] Gastroenterology. 1994 Jun;106(6):1589-95 [8194706.001]
  • [Cites] Stat Med. 1994 May 15;13(9):955-68 [8047747.001]
  • [Cites] Gut. 1994 Oct;35(10):1348-51 [7959183.001]
  • [Cites] Cancer. 1995 Jan 15;75(2):423-9 [7812911.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jan 3;92(1):151-5 [7816807.001]
  • [Cites] Br J Surg. 1994 Dec;81(12):1766-8 [7827934.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1994;59:577-83 [7587115.001]
  • [Cites] Gastroenterology. 2003 Jan;124(1):47-56 [12512029.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):776-81 [12552134.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):368-78 [11331953.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1607-19 [11375943.001]
  • [Cites] Gastroenterology. 2001 Jun;120(7):1630-9 [11375945.001]
  • [Cites] Ann Thorac Surg. 2001 Aug;72(2):334-9; discussion 339-41 [11515862.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):592-8 [11522743.001]
  • [Cites] Am J Gastroenterol. 2001 Sep;96(9):2575-83 [11569678.001]
  • [Cites] Am J Gastroenterol. 2001 Oct;96(10):2839-48 [11693316.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8284-9 [11719461.001]
  • [Cites] Am J Gastroenterol. 2001 Nov;96(11):3071-83 [11721752.001]
  • [Cites] Gastrointest Endosc. 2001 Dec;54(6):682-8 [11726842.001]
  • [Cites] Neoplasia. 2002 Mar-Apr;4(2):121-8 [11896567.001]
  • [Cites] Gastroenterology. 2002 Apr;122(4):1101-12 [11910360.001]
  • [Cites] N Engl J Med. 2002 Apr 11;346(15):1128-37 [11948273.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9433-8 [12093899.001]
  • [Cites] Surg Oncol Clin N Am. 2002 Apr;11(2):235-56 [12424848.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2002 Nov;14(11):1179-86 [12439111.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16226-31 [12446840.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Dec 24;99(26):16910-5 [12486240.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Jun;18(6):683-9 [12753151.001]
  • [Cites] Clin Cancer Res. 2003 Jul;9(7):2560-6 [12855631.001]
  • [Cites] Gut. 2003 Aug;52(8):1081-4 [12865262.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4211-7 [12874028.001]
  • [Cites] Clin Cancer Res. 2003 Aug 1;9(8):2912-9 [12912936.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):695-701 [12951588.001]
  • [Cites] Hum Pathol. 1988 Feb;19(2):166-78 [3343032.001]
  • [Cites] Am J Pathol. 1988 Apr;131(1):53-61 [3354644.001]
  • [Cites] Gastroenterology. 1989 Feb;96(2 Pt 1):355-67 [2910757.001]
  • [Cites] Lab Invest. 1989 Jan;60(1):65-71 [2911184.001]
  • [Cites] Lab Invest. 1989 Mar;60(3):418-32 [2927081.001]
  • [Cites] Stat Med. 1989 Apr;8(4):431-40 [2727467.001]
  • [Cites] Gastroenterology. 1989 Oct;97(4):815-20 [2777038.001]
  • [Cites] J Natl Cancer Inst. 2004 Jun 2;96(11):885-7; author reply 887 [15173278.001]
  • [Cites] J Pathol. 2004 Jul;203(3):780-8 [15221937.001]
  • [Cites] Gastroenterology. 2004 Jul;127(1):310-30 [15236196.001]
  • [Cites] Oncogene. 2007 Sep 20;26(43):6332-40 [17452981.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2649-55 [18086770.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):111-7 [18199717.001]
  • [Cites] Aliment Pharmacol Ther. 2008 Feb 15;27(4):316-20 [18062791.001]
  • [Cites] Int J Cancer. 2008 Mar 15;122(6):1303-10 [18000824.001]
  • [Cites] Am J Gastroenterol. 2008 Mar;103(3):788-97 [18341497.001]
  • [Cites] PLoS One. 2008;3(4):e1890 [18382671.001]
  • [Cites] Cancer Res. 2008 Jun 1;68(11):4163-72 [18519675.001]
  • [Cites] Dig Liver Dis. 2008 Jul;40(7):510-22 [18400571.001]
  • [Cites] Gut. 2008 Aug;57(8):1041-8 [18305067.001]
  • [Cites] Am J Epidemiol. 2008 Aug 1;168(3):237-49 [18550563.001]
  • [Cites] Hum Pathol. 2008 Aug;39(8):1128-35 [18602665.001]
  • [Cites] Genome Res. 2008 Sep;18(9):1518-29 [18577705.001]
  • [Cites] Science. 2008 Sep 5;321(5894):1280-1 [18772403.001]
  • [Cites] Gut. 2008 Oct;57(10):1354-9 [18424568.001]
  • [Cites] Int J Cancer. 2008 Nov 15;123(10):2331-6 [18729198.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1801-6 [18772397.001]
  • [Cites] Dis Esophagus. 2008;21(6):529-38 [18840137.001]
  • [Cites] Mol Cancer. 2008;7:75 [18831746.001]
  • [Cites] Gastroenterology. 2008 Oct;135(4):1392-1413, 1413.e1-5 [18801365.001]
  • [Cites] Clin Cancer Res. 2008 Nov 1;14(21):6988-95 [18980994.001]
  • [Cites] PLoS One. 2008;3(11):e3809 [19043591.001]
  • [Cites] Cancer Prev Res (Phila). 2008 Nov;1(6):413-23 [19138988.001]
  • [Cites] Nat Genet. 2009 Feb;41(2):178-86 [19151715.001]
  • [Cites] Cell Cycle. 2009 Mar 15;8(6):809-17 [19229128.001]
  • [Cites] Cancer Biomark. 2009;5(3):143-58 [19407369.001]
  • [Cites] Clin Cancer Res. 2009 May 15;15(10):3305-14 [19417022.001]
  • [Cites] Gastrointest Endosc. 1999 Dec;50(6):814-8 [10570342.001]
  • [Cites] J Natl Cancer Inst. 1999 Dec 15;91(24):2087-95 [10601379.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Hum Pathol. 2000 Jan;31(1):35-9 [10665910.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):555-66 [10666385.001]
  • [Cites] Cancer Causes Control. 2000 Mar;11(3):231-8 [10782657.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1702-10 [10815888.001]
  • [Cites] Am J Gastroenterol. 2000 Jul;95(7):1669-76 [10925966.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 16;92(16):1316-21 [10944553.001]
  • [Cites] Am J Gastroenterol. 2000 Aug;95(8):1888-93 [10950031.001]
  • [Cites] Genome Res. 2000 Aug;10(8):1126-37 [10958631.001]
  • [Cites] Cancer Res. 2000 Sep 15;60(18):5021-6 [11016622.001]
  • [Cites] BMJ. 2000 Nov 18;321(7271):1252-5 [11082084.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):3164-70 [11306503.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Dec;38(4):302-6 [14566848.001]
  • [Cites] Mod Pathol. 2004 May;17(5):588-96 [15017433.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3414-27 [15150093.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 May;4(5):566-72 [16630761.001]
  • [Cites] Gut. 2006 Jun;55(6):764-74 [16368780.001]
  • [Cites] Oncogene. 2006 May 18;25(21):3084-92 [16407829.001]
  • [Cites] Am J Gastroenterol. 2006 Aug;101(8):1900-20; quiz 1943 [16928254.001]
  • [Cites] Gut. 2006 Oct;55(10):1390-7 [16682429.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1935-40 [17035402.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Clin Cancer Res. 2006 Nov 15;12(22):6637-42 [17121882.001]
  • [Cites] Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):659-65 [17255290.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):509-16 [16537709.001]
  • [Cites] Nat Genet. 2006 Apr;38(4):468-73 [16565718.001]
  • [Cites] Cancer Genet Cytogenet. 1989 Oct 15;42(2):281-6 [2790761.001]
  • [Cites] Science. 1990 Jan 5;247(4938):49-56 [2294591.001]
  • [Cites] Cancer Res. 1991 Jun 15;51(12):3075-9 [2039987.001]
  • [Cites] Surg Oncol. 1995 Jun;4(3):163-71 [7582189.001]
  • [Cites] Cancer Res. 1996 Jan 15;56(2):259-63 [8542577.001]
  • [Cites] Oncogene. 1996 May 2;12(9):1873-8 [8649847.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3225-9 [11309270.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3410-8 [11309301.001]
  • [Cites] Gut. 2003 May;52(5):623-8 [12692043.001]
  • [Cites] Cancer. 1995 Oct 1;76(7):1116-9 [8630885.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7081-4 [8692948.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4499-502 [8813147.001]
  • [Cites] Am J Clin Pathol. 1996 Sep;106(3):298-304 [8816585.001]
  • [Cites] Gut. 1996 Jul;39(1):5-8 [8881798.001]
  • [Cites] Oncogene. 1996 Nov 7;13(9):1867-73 [8934532.001]
  • [Cites] Am J Gastroenterol. 1997 Apr;92(4):586-91 [9128304.001]
  • [Cites] Surg Oncol Clin N Am. 1997 Jul;6(3):515-31 [9210354.001]
  • [Cites] J Clin Invest. 1997 Oct 15;100(8):2133-7 [9329980.001]
  • [Cites] Oncogene. 1997 Oct 2;15(14):1653-9 [9349498.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Feb;7(2):97-102 [9488582.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):641-51 [9708926.001]
  • [Cites] Br J Cancer. 1998 Oct;78(7):950-7 [9764589.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Oct 1;106(1):11-7 [9772903.001]
  • [Cites] Gastroenterology. 1998 Dec;115(6):1381-6 [9834265.001]
  • [Cites] JAMA. 1998 Nov 25;280(20):1747-51 [9842949.001]
  • [Cites] Cytometry. 1998 Dec 15;34(6):257-63 [9879642.001]
  • [Cites] N Engl J Med. 1999 Mar 18;340(11):825-31 [10080844.001]
  • [Cites] Nat Genet. 1999 May;22(1):106-9 [10319873.001]
  • [Cites] Am J Pathol. 1999 Apr;154(4):965-73 [10233832.001]
  • [Cites] Gastrointest Endosc. 1999 Jul;50(1):23-6 [10385717.001]
  • [Cites] Clin Cancer Res. 1999 Jul;5(7):1862-7 [10430093.001]
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4784-7 [10519384.001]
  • [Cites] Surgery. 1957 Jun;41(6):881-94 [13442856.001]
  • [Cites] Semin Cancer Biol. 2005 Feb;15(1):51-60 [15613288.001]
  • [Cites] Cancer Lett. 2005 Jan 20;217(2):221-30 [15617840.001]
  • [Cites] J Natl Cancer Inst. 2005 Jan 19;97(2):142-6 [15657344.001]
  • [Cites] Neoplasia. 2004 Nov-Dec;6(6):751-60 [15720801.001]
  • [Cites] Am J Gastroenterol. 2005 Apr;100(4):775-83 [15784018.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):830-4 [15824152.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3146-54 [15833844.001]
  • [Cites] Oncogene. 2005 Jun 9;24(25):4138-48 [15824739.001]
  • [Cites] Int J Cancer. 2005 Sep 10;116(4):584-91 [15825175.001]
  • [Cites] Gastrointest Endosc. 2005 Oct;62(4):488-98 [16185958.001]
  • [Cites] Gastroenterology. 2005 Oct;129(4):1274-81 [16230080.001]
  • [Cites] Neoplasia. 2005 Sep;7(9):854-61 [16229808.001]
  • [Cites] Lancet Oncol. 2005 Dec;6(12):945-52 [16321762.001]
  • [Cites] J Pathol. 2006 Jan;208(1):100-7 [16278815.001]
  • [Cites] Gastroenterology. 2005 Dec;129(6):1825-31 [16344051.001]
  • [Cites] Nat Rev Genet. 2006 Jan;7(1):21-33 [16369569.001]
  • [Cites] Am J Gastroenterol. 2005 Dec;100(12):2616-21 [16393209.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 17;95(18):1404-13 [13130116.001]
  • [Cites] Am J Gastroenterol. 2003 Sep;98(9):1931-9 [14499768.001]
  • [Cites] Clin Cancer Res. 2007 Nov 1;13(21):6293-300 [17975140.001]
  • [Cites] Aliment Pharmacol Ther. 2007 Dec;26(11-12):1465-77 [17900269.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 Dec;293(6):G1106-13 [17932229.001]
  • [Cites] Cancer Res. 2004 Oct 15;64(20):7629-33 [15492292.001]
  • [Cites] Science. 1976 Oct 1;194(4260):23-8 [959840.001]
  • [Cites] Gastroenterology. 1978 Oct;75(4):683-7 [710836.001]
  • [Cites] Arch Surg. 1983 May;118(5):543-9 [6838359.001]
  • [Cites] Gastroenterology. 1987 Jul;93(1):1-11 [3582897.001]
  • [Cites] Am J Gastroenterol. 1987 Oct;82(10):1012-5 [3661507.001]
  • [Cites] Gastroenterology. 1988 Jan;94(1):81-90 [3335302.001]
  • (PMID = 22112482.001).
  • [ISSN] 1875-8592
  • [Journal-full-title] Cancer biomarkers : section A of Disease markers
  • [ISO-abbreviation] Cancer Biomark
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA091955; United States / NCI NIH HHS / CA / P01CA91955
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ NIHMS578448; NLM/ PMC4026269
  •  go-up   go-down






Advertisement